公开(公告)号：US09782466B2

公开(公告)日：2017-10-10

申请号：US12321418

申请日：2009-01-20

申请人： Paolo Constantino

发明人： Paolo Constantino

IPC分类号： A61K39/385 ,  A61K45/00 ,  A61K47/00 ,  A61K39/00 ,  A61K39/095 ,  A61K39/102 ,  A61K39/09 ,  A61K39/08 ,  C09F1/02 ,  A23J1/00 ,  C07K1/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C07K1/06 ,  C07K1/08 ,  C09F1/00 ,  A23J1/04 ,  A61K38/00 ,  A23J1/20 ,  C07H15/04 ,  C07K14/22 ,  C07K14/285 ,  A61K38/48

CPC分类号： A61K39/095 ,  A23J1/04 ,  A23J1/205 ,  A61K38/00 ,  A61K38/4893 ,  A61K39/092 ,  A61K39/102 ,  A61K39/39 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/6037 ,  C07H15/04 ,  C07K14/22 ,  C07K14/285 ,  C09F1/00 ,  C09G1/00 ,  Y02A50/466 ,  Y10S424/831

摘要： Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.

公开(公告)号：US20170274068A1

公开(公告)日：2017-09-28

申请号：US15509997

申请日：2015-09-11

申请人： THE UNIVERSITY OF MELBOURNE

发明人： DAVID CHARLES JACKSON ,  BRENDON YEW LOONG CHUA ,  TOSHIKI SEKIYA

IPC分类号： A61K39/39 ,  A61K39/095 ,  A61K45/06 ,  A61K33/42

CPC分类号： A61K39/39 ,  A61K33/42 ,  A61K39/00 ,  A61K39/095 ,  A61K45/06 ,  A61K47/542 ,  A61K47/60 ,  A61K47/645 ,  A61K47/646 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/6093 ,  C07K2319/40

摘要： The present invention provides an immunogenic composition comprising a charged antigen electrostatically associated with a Toll-Like Receptor (TLR) targeting moiety. The TLR targeting moiety comprises a TLR-2 agonist covalently attached to polyethylene glycol and to a hyper-branched charged peptide.

公开(公告)号：US09771399B2

公开(公告)日：2017-09-26

申请号：US14927052

申请日：2015-10-29

申请人： GlaxoSmithKline Biologicals SA

发明人： Jeannette Adu-Bobie ,  Mariagrazia Pizza ,  Nathalie Norais ,  Germano Ferrari ,  Guido Grandi

IPC分类号： C07K14/22 ,  A61K39/095 ,  C07K14/245 ,  C12N9/10 ,  A61K39/108 ,  A61K39/00

CPC分类号： C07K14/245 ,  A61K39/00 ,  A61K39/0258 ,  A61K39/095 ,  C07K14/22 ,  C12N9/1051 ,  Y02A50/474

摘要： Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titers than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.

公开(公告)号：US09757444B2

公开(公告)日：2017-09-12

申请号：US14820452

申请日：2015-08-06

申请人： Wyeth Holdings LLC

发明人： Gary W. Zlotnick ,  Leah Diane Fletcher ,  John Erwin Farley ,  Liesel A. Bernfield ,  Robert J. Zagursky ,  Benjamin J. Metcalf

IPC分类号： A61K39/095 ,  A61K39/00 ,  A61K39/39 ,  C07K14/22 ,  C07K16/12 ,  A61K47/48 ,  G01N33/569 ,  C12N9/28 ,  C12N9/40 ,  C12N9/38

CPC分类号： A61K39/095 ,  A61K39/00 ,  A61K39/39 ,  A61K47/543 ,  A61K47/646 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/58 ,  A61K2039/6087 ,  C07K14/22 ,  C07K16/1217 ,  C12N9/2417 ,  C12N9/2465 ,  C12N9/2471 ,  G01N33/56911 ,  G01N2333/22 ,  Y10S530/825

摘要： The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

公开(公告)号：US20170252699A1

公开(公告)日：2017-09-07

申请号：US15599556

申请日：2017-05-19

申请人： GLAXOSMITHKLINE BIOLOGICALS S.A.

发明人： Roberto OLIVIERI ,  Fabio SABBATINI ,  Ilio MARSILI

IPC分类号： B01D61/14 ,  A61K39/095

CPC分类号： B01D61/145 ,  A61K39/095 ,  A61K2039/6018 ,  B01D61/147 ,  B01D61/16 ,  B01D2311/04 ,  B01D2311/16 ,  C07K14/22 ,  C12N1/00 ,  C12N1/005 ,  C12N1/02 ,  C12N1/06 ,  C12N1/20 ,  C12R1/01 ,  C12R1/36 ,  B01D2311/2676

摘要： In place of a step of centrifugation during preparation of outer membrane vesicles (OMVs) from bacteria, the invention utilises ultrafiltration. This allows much larger amounts of OMV-containing supernatant to be processed in a much shorter time. Thus the invention provides a process for preparing bacterial OMVs, comprising a step of ultrafiltration. The ultrafiltration step is performed on an aqueous suspension of OMVs after they have been prepared from bacteria and the OMVs remain in suspension after the filtration step. The invention is particularly useful for preparing OMVs from Neisseria meningitidis.

公开(公告)号：US09707154B2

公开(公告)日：2017-07-18

申请号：US14259270

申请日：2014-04-23

申请人： Corning Incorporated

发明人： Wendell P. Weeks ,  Robert Anthony Schaut ,  Steven Edward DeMartino ,  John Stephen Peanasky

IPC分类号： A61K39/395 ,  A61J1/00 ,  C03C3/087 ,  C03C3/091 ,  C03C4/20 ,  C03C21/00 ,  A61K39/095 ,  A61K38/22 ,  C07K16/22 ,  C07K16/24 ,  A61K39/00

CPC分类号： A61J1/00 ,  A61K38/2221 ,  A61K39/095 ,  A61K2039/505 ,  A61K2039/54 ,  C03C3/087 ,  C03C3/091 ,  C03C4/20 ,  C03C21/002 ,  C07K16/22 ,  C07K16/244 ,  C07K2317/73 ,  C07K2317/94

摘要： The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LUCENTIS® (ranibizumab), BEXSERO® (meningococcal group B vaccine [rDNA, component, adsorbed]), AIN457 (secukinumab) or RELAXIN® (serelaxin).

公开(公告)号：US20170165346A1

公开(公告)日：2017-06-15

申请号：US15438584

申请日：2017-02-21

申请人： GlaxoSmithKline Biologicals SA

发明人： Marzia Monica GIULIANI ,  Mariagrazia PIZZA ,  Rino RAPPUOLI

IPC分类号： A61K39/095

摘要： Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae.

公开(公告)号：US20170157241A1

公开(公告)日：2017-06-08

申请号：US15310055

申请日：2015-05-08

申请人： KANVAX BIOPHARMACEUTICALS LTD

发明人： Jianping LI

IPC分类号： A61K39/385 ,  A61K39/095 ,  A61K39/09 ,  A61K39/39 ,  A61K39/102

摘要： The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided. Methods of preparing the compositions, and methods for treating or preventing bacterial infections are further provided. The compositions and methods are useful for enhancing immune response in young children, elderly and immunocompromised individuals.

公开(公告)号：US20170143821A1

公开(公告)日：2017-05-25

申请号：US14764953

申请日：2014-01-29

申请人： BIOSYNTH S.R. L.

发明人： Massimo PORRO

IPC分类号： A61K39/385 ,  A61K39/095 ,  A61K39/102 ,  A61K39/09

CPC分类号： A61K39/385 ,  A61K39/092 ,  A61K39/095 ,  A61K39/102 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/645 ,  A61K2039/70

摘要： The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S. pneumoniae, N. meningitidis, H. influenzae, K. pneumoniae, M. tuberculosis, S. aureus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.

公开(公告)号：US20170080077A1

公开(公告)日：2017-03-23

申请号：US15368435

申请日：2016-12-02

申请人： GlaxoSmithKline Biologicals SA

发明人： Maria ARICÒ ,  Maurizio COMANDUCCI ,  Cesira GALEOTTI ,  Vega MASIGNANI ,  Marzia Monica GIULIANI ,  Mariagrazia PIZZA

IPC分类号： A61K39/095

CPC分类号： A61K39/095 ,  A61K38/00 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/572 ,  A61K2039/575 ,  C07K14/22 ,  C07K2319/00 ,  C12P21/00 ,  C12P21/02 ,  C12Q1/689 ,  C12Q2600/156

摘要： Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.